New Fast-Acting insulin pump treatment shows promise for type 2 diabetes

NCT ID NCT07068295

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new fast-acting insulin called NNC0471-0119 in 65 adults with type 2 diabetes who use an insulin pump. Researchers compared how quickly the new insulin enters the bloodstream and lowers blood sugar versus a standard insulin (insulin aspart). The goal is to see if the new insulin works faster and is safe for pump use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NNC0471-0119 (a fast-acting insulin) and insulin aspart (comparator)
What this could lead to: If successful, this could lead to a faster-acting insulin option for insulin pumps, potentially improving blood sugar control after meals for people with type 2 diabetes.
What could go wrong: This is an early phase 1 study with only 65 participants, so results may not apply to everyone. The new insulin may not work better or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Profil Institut für Stoffwechselforschung GmbH

Neuss, 41460, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.